Phase 1 study of HSP105-derived peptide vaccine for patients with advanced esophageal cancer/ colo- rectal cancer.
Phase 1
- Conditions
- advanced esophageal cancer/ colo- rectal cancer
- Registration Number
- JPRN-UMIN000017809
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pleural effusion or ascites required invasive treatment. 2) Chemotherapy within 4 weeks prior to enrollment. 3) Active infection requires systemic therapy. 4) Any severe medical conditions. 5) Historical or coexisting severe interstitial pneumonia. 6) Severe psychiatric disorder. 7) Women during pregnancy or lactation , 8) Known serious drug allergy. 9) Positive HBs antigen or HCV antibody or HIV antibody within 6 months prior to enrollment. 10) Received the continuous whole body dosage (oral or intravenous) with steroid and other immunosuppressive drugs. 11) Patient is judged by the investigator to be inappropriate for study participation for any reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method P1a:Proportion of dose limiting toxicity P1b:Response rate
- Secondary Outcome Measures
Name Time Method Progression free survival Treatment failure rate Adverse events Immunological effects